SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
SCIENTURE (NASDAQ:SCNX) has secured a major PBM-led GPO rebate agreement for Arbli™ (losartan potassium), their FDA-approved liquid formulation of losartan. This agreement advances formulary access with health plans covering over 100 million lives.
Arbli™ is the first and only ready-to-use liquid losartan in the U.S., targeting the $256 million losartan market with 71 million prescriptions annually. The product is approved for treating hypertension in patients over six years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in certain type 2 diabetes patients.
The proprietary formulation offers advantages including reduced dosing volume, room-temperature stability, and elimination of compounding needs, protected by two USPTO patents listed in the FDA Orangebook.
SCIENTURE (NASDAQ:SCNX) ha perfezionato un importante accordo PBM-led GPO per Arbli™ (losartan potassico), la formulazione liquida approvata dalla FDA di losartan. Questo accordo migliora l’accesso al formulario con i piani sanitari che coprono oltre 100 milioni di assicurati.
Arbli™ è la prima e unica losartan liquido pronta all’uso negli Stati Uniti, mirata al mercato losartan da 256 milioni di dollari con 71 milioni di prescrizioni all’anno. Il prodotto è approvato per trattare l’ipertensione in pazienti di età superiore ai sei anni, per ridurre il rischio di ictus in ipertesi con ipertrofia del ventricolo sinistro e per trattare la nefropatia diabetica in alcuni pazienti con diabete di tipo 2.
La formulazione proprietaria offre vantaggi quali volume di dosaggio ridotto, stabilità a temperatura ambiente e eliminazione della necessità di preparazioni, protetta da due brevetti USPTO elencati nel FDA Orange Book.
SCIENTURE (NASDAQ:SCNX) ha asegurado un importante acuerdo de rebate GPO liderado por PBM para Arbli™ (losartán potásico), su formulación líquida aprobada por la FDA de losartán. Este acuerdo facilita el acceso al formulario con planes de salud que cubren a más de 100 millones de asegurados.
Arbli™ es el primer y único losartán líquido listo para usar en EE. UU., dirigido al mercado de losartán de 256 millones de dólares con 71 millones de recetas al año. El producto está aprobado para tratar la hipertensión en pacientes mayores de seis años, reducir el riesgo de ictus en hipertensos con hipertrofia del ventrículo izquierdo y tratar la nefropatía diabética en ciertos pacientes con diabetes tipo 2.
La formulación propietaria ofrece ventajas como dosis reducida, estabilidad a temperatura ambiente y eliminación de la necesidad de preparación, protegida por dos patentes USPTO listadas en el FDA Orange Book.
SCIENTURE (NASDAQ:SCNX)는 Arbli™ (로르탄 potassium)의 FDA 승인 액체 제형인 로르탄에 대해 PBM이 주도하는 GPO 환급 계약을 대형으로 확보했습니다. 이 계약은 건강 계획이 1억 명 이상의 생명을 커버하는 포뮬러리 접근성을 촉진합니다.
Arbli™는 미국에서 최초이자 유일하게 바로 사용할 수 있는 로르탄 액상 제제로, $256백만 시장의 로르탄 시장을 대상으로 연간 7,100만 건의 처방전을 예상합니다. 이 제품은 6세 이상 환자의 고혈압 치료, 좌심실 비대 고혈압 환자의 뇌졸중 위험 감소, 특정 제2형 당뇨병 환자의 당뇨병성 신병증 치료에 승인을 받았습니다.
독점 제형은 투여 용량 감소, 상온 안정성, 조제 필요성의 제거 등의 이점을 제공하며, FDA Orange Book에 기재된 두 개의 USPTO 특허로 보호됩니다.
SCIENTURE (NASDAQ:SCNX) a sécurisé un important accord PBM-led GPO pour Arbli™ (losartan potassique), leur formulation liquide approuvée par la FDA du losartan. Cet accord renforce l’accès au formulaire avec des plans de santé couvrant plus de 100 millions de personnes assurées.
Arbli™ est le premier et seul losartan liquide prêt à l’emploi aux États‑Unis, ciblant le marché du losartan de 256 millions de dollars avec 71 millions de prescriptions annuelles. Le produit est approuvé pour traiter l’hypertension chez les patients de plus de six ans, réduire le risque d’AVC chez les hypertendus avec hypertrophie du ventricule gauche et traiter la néphropathie diabétique chez certains patients diabétiques de type 2.
La formulation propriétaire offre des avantages tels qu’un volume de dosage réduit, une stabilité à température ambiante et l’élimination de la préparation, protégée par deux brevets USPTO répertoriés dans l’Orange Book de la FDA.
SCIENTURE (NASDAQ:SCNX) hat eine bedeutende PBM-gesteuerte GPO-Rabattvereinbarung für Arbli™ (Losartankalium), ihre von der FDA genehmigte flüssige Formulierung von Losartan, gesichert. Diese Vereinbarung verbessert den Formularzugang mit Gesundheitsplänen, die über 100 Millionen Menschen versichern coverage haben.
Arbli™ ist das erste und einzige gebrauchsfertige flüssige Losartan in den USA und richtet sich an den 256-Millionen-Dollar-Losartan-Markt mit 71 Millionen Verschreibungen pro Jahr. Das Produkt ist zugelassen zur Behandlung von Bluthochdruck bei Patienten über sechs Jahre, zur Senkung des Schlaganfallrisikos bei Hypertonikern mit hypertrophierter linkem Ventrikel und zur Behandlung der diabetischen Nephropathie bei bestimmten Typ-2-Diabetikern.
Die proprietäre Formulierung bietet Vorteile wie ein reduziertes Dosierungvolumen, Stabilität bei Raumtemperatur und Wegfall der Apothekenherstellung, geschützt durch zwei USPTO-Patente, die im FDA Orange Book aufgeführt sind.
SCIENTURE (NASDAQ:SCNX) قد أمنت اتفاقاً هاماً على شكل rebate GPO بقيادة PBM لـ Arbli™ (لورسartan البوتاسيوم)، الصيغة السائلة المعتمدة من FDA للوسارتان. يعزز هذا الاتفاق الوصول إلى التخصصات الدوائية عبر خطط صحية تغطي أكثر من 100 مليون شخص.
Arbli™ هو الأول والوحيد من اللوسارتان السائل الجاهز للاستخدام في الولايات المتحدة، مستهدفاً السوق البالغ 256 مليون دولار من اللوران مع 71 مليون وصفة سنوياً. المنتج معتمد لعلاج ارتفاع ضغط الدم لدى المرضى الذين تزيد أعمارهم عن ست سنوات، وتقليل مخاطر السكتة الدماغية لدى مرضى ارتفاع ضغط الدم المصابين بتضخم بطين القلب الأيسر، وعلاج الاعتلال الكلوي السكري عند بعض مرضى النوع 2 من السكري.
الصيغة الملكية تقدم مزايا مثل تقليل حجم الجرعة، الثبات في درجات حرارة الغرفة، وإلغاء الحاجة إلى التحضير، محمية ببراءتين من USPTO مدرجتين في FDA Orange Book.
SCIENTURE (纳斯达克:SCNX) 已为 Arbli™（洛沙坦钾盐）获得了一项由PBM牵头的GPO回扣协议，这是其FDA批准的洛沙坦口服液形式。该协议通过覆盖超过 1亿人群 的健康计划，进一步提升了列入药品目录的可及性。
Arbli™ 是美国第一且唯一现成可用的洛沙坦口服液，面向 2.56亿美元洛沙坦市场，年处方量约为7100万张。该药物获批用于治疗六岁及以上患者的高血压，在左心室肥厚的高血压患者中降低中风风险，并治疗某些2型糖尿病患者的糖尿病肾病。
该独家配方具有用药体积更小、室温稳定、无需配制等优点，并受两项USPTO专利保护，列在FDA的Orange Book中。
- Secured major PBM-led GPO rebate agreement covering over 100 million lives
- First and only FDA-approved ready-to-use liquid losartan in the $256M U.S. market
- Protected by two USPTO patents listed in FDA Orangebook
- Targets large market with 71 million annual prescriptions
- Eliminates compounding needs while offering improved stability and dosing accuracy
- Entering competitive market dominated by established solid oral formulations
- Will require significant market education to drive adoption from traditional tablet form
Insights
SCIENTURE secures major PBM rebate agreement for Arbli, potentially unlocking significant revenue opportunities in $256M losartan market.
SCIENTURE's announcement represents a critical market access milestone for Arbli, their liquid losartan formulation. The PBM-led GPO rebate agreement advances formulary placement with health plans covering over 100 million lives - a substantial portion of the insured U.S. population. This significantly reduces reimbursement barriers that typically limit uptake for new formulations.
The U.S. losartan market presents a $256 million opportunity with 71 million annual prescriptions, according to IQVIA data. While Arbli won't capture the entire market, its unique position as the first and only FDA-approved ready-to-use liquid losartan gives it a defensible niche for patients who struggle with tablets or require precise dosing.
The product's two issued patents listed in the FDA Orange Book provide market exclusivity, enhancing its commercial potential. Importantly, Arbli addresses specific clinical needs - eliminating compounding requirements, offering reduced dosing volume, and providing extended room-temperature shelf life.
This agreement demonstrates SCIENTURE's execution capability in navigating complex PBM negotiations, historically a significant barrier for specialty pharmaceutical products. By securing this rebate structure, the company has effectively aligned financial incentives for PBMs and health plans, potentially accelerating prescription growth while maintaining acceptable margins.
Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life
COMMACK, NY, Sept. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has formalized a major commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement, advancing the process of securing formulary access with health plans covering more than 100 million lives for ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL. Additional discussions are underway to further expand both commercial and government coverage for the product.
ArbliTM is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. ArbliTM is the first and only FDA approved, ready-to-use oral liquid losartan available in the U.S.
ArbliTM is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension.. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ ensures consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. ArbliTM has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
According to IQVIA data (MAT June 2025), the U.S. losartan market represents approximately
“This is an important milestone that reflects our commitment to ensuring that patients who need ArbliTM can access it affordably,” said Narasimhan Mani, President and co-CEO. “By signing the rebate agreement, we are in the process of securing formulary access with health plans covering more than 100 million lives and positioning Arbli™ for rapid adoption in the
“Securing this rebate GPO agreement is a significant accomplishment in our commitment to expand patient access to ArbliTM,” remarked Shankar Hariharan, Executive Chairman and co-CEO. “Through this partnernship, we are enabling health plans and providers to deliver better care while driving greater efficiency in the healthcare system.”
About ArbliTM
ArbliTM is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
ArbliTM is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
IMPORTANT SAFETY INFORMATION
- Do not take ArbliTM when pregnant. When pregnancy is detected, discontinue ArbliTM as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ArbliTM can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
- Do not co-administer ArbliTM with aliskiren in patients with diabetes. Avoid use of aliskiren with ArbliTM in patients with renal impairment (GFR <60 mL/min).
- Do not administer ArbliTM in patients with severe hepatic impairment. ArbliTM has not been studied in patients with severe hepatic impairment.
- The most common adverse reactions are (incidence ≥
2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About Hypertension
Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com
FAQ
What is the market size for Arbli by SCIENTURE (NASDAQ:SCNX)?
How many lives are covered under SCIENTURE's new PBM-led GPO rebate agreement?
What are the approved indications for Arbli (losartan potassium)?
What makes Arbli different from other losartan products?
How is SCIENTURE's Arbli protected from competition?
